WEBULL
News
UTHR
468.93
-0.90%
-4.27
Press Release: United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
Dow Jones · 5h ago
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results
Reuters · 5h ago
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
Barchart · 11h ago
United Therapeutics President and COO Michael Benkowitz Reports Disposal of Common Shares
Reuters · 19h ago
United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial
TipRanks · 1d ago
Weekly Report: what happened at UTHR last week (0202-0206)?
Weekly Report · 2d ago
Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data
Simply Wall St · 5d ago
United Therapeutics EVP & General Counsel Paul A. Mahon Reports Disposal of Common Shares
Reuters · 5d ago
United Therapeutics: In Progress -- New Organs For Old At Scale
Seeking Alpha · 6d ago
Noteworthy Wednesday Option Activity: FHN, UTHR, SLAB
NASDAQ · 6d ago
United Therapeutics Director Jan Malcolm Reports Sale of Common Shares
Reuters · 02/03 21:32
United Therapeutics President and COO Michael Benkowitz Reports Disposal of Common Shares
Reuters · 02/03 21:31
Positive miroliverELAP Phase 1 Data Could Be A Game Changer For United Therapeutics (UTHR)
Simply Wall St · 02/03 04:43
Weekly Report: what happened at UTHR last week (0126-0130)?
Weekly Report · 02/02 09:28
United Therapeutics President and COO Michael Benkowitz Reports Disposal of Common Shares
Reuters · 01/28 21:31
Early miroliverELAP Safety Data Might Change The Case For Investing In United Therapeutics (UTHR)
Simply Wall St · 01/27 03:25
United Therapeutics Reports Early Success For External Liver Support In Acute Failure
Benzinga · 01/26 13:55
United Therapeutics Reports Positive Phase 1 Results for Bioengineered Liver Device in Acute Liver Failure
Reuters · 01/26 12:06
United Therapeutics Says Phase 1 Study Of MiroliverELAP, An External Liver Assist Product, For Acute Liver Failure Met The Primary Endpoint Of Survival
Benzinga · 01/26 12:05
UNITED THERAPEUTICS CORP - NO UNEXPECTED SERIOUS ADVERSE EVENTS REPORTED
Reuters · 01/26 12:00
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.